Cumberland acquires portfolio of injectable methotrexate products

US specialty drugmaker Cumberland Pharmaceuticals (Nasdaq: CPIX) has entered into an agreement to acquire the exclusive US rights to privately held Nordic Group’s innovative injectable methotrexate product line.

The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. The product line is approved for patient use in various European countries. Cumberland will register and commercialize the methotrexate products in the USA.

Under the terms of the agreement, Cumberland will be responsible for the products' Food and Drug Administration submission and registration. The regulatory submission, expected to occur during the first half of 2017, will be based on the dossier provided by Nordic. Following registration, Cumberland will be responsible for product launch and commercialization, including all marketing, promotion, and distribution of the products in the USA.